`(Table presents the data on ITU Unit Action)
`
`77309541
`
`0000000
`
`PRINCIPAL
`
`N/A
`
`OVERVIEW
`
`FILING DATE
`
`REG DATE
`
`MARK TYPE
`
`INTL REG DATE
`
`BESCH, JAY C
`
`L.O. ASSIGNED
`
`PUB INFORMATION
`
`08/03/2010
`
`10/07/2008
`
`606-ABANDONED - NO STATEMENT OF USE FILED
`
`SERIAL NUMBER
`
`REG NUMBER
`
`REGISTER
`
`INTL REG #
`
`TM ATTORNEY
`
`RUN DATE
`
`PUB DATE
`
`STATUS
`
`10/22/2007
`
`N/A
`
`TRADEMARK
`
`N/A
`
`108
`
`STATUS DATE
`
`08/02/2010
`
`LITERAL MARK ELEMENT
`
`STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INIHIBITS LP-PLA2 WITH ANTI-
`INFLAMMATORY AND PLAQUE STABILISING EFFECTS
`
`DATE ABANDONED
`
`08/02/2010
`
`DATE CANCELLED
`
`SECTION 2F
`
`SECTION 8
`
`SECTION 15
`
`RENEWAL FILED
`
`NO
`
`NO
`
`NO
`
`NO
`
`N/A
`
`SECTION 2F IN PART
`
`SECTION 8 IN PART
`
`REPUB 12C
`
`RENEWAL DATE
`
`N/A
`
`NO
`
`NO
`
`N/A
`
`N/A
`
`DATE AMEND REG
`
`1 (a)
`
`1 (b)
`
`44D
`
`44E
`
`66A
`
`NO BASIS
`
`FILED BASIS
`
`FILING BASIS
`
`CURRENT BASIS
`
`AMENDED BASIS
`
`NO
`
`YES
`
`NO
`
`NO
`
`NO
`
`NO
`
`1 (a)
`
`1 (b)
`
`44D
`
`44E
`
`66A
`
`NO BASIS
`
`1 (a)
`
`1 (b)
`
`44D
`
`44E
`
`NO
`
`YES
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`NO
`
`STANDARD CHARACTER MARK
`
`LITERAL MARK ELEMENT
`
`MARK DRAWING CODE
`
`COLOR DRAWING FLAG
`
`PARTY TYPE
`
`NAME
`
`ADDRESS
`
`MARK DATA
`
`YES
`
`STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB
`INIHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING
`EFFECTS
`
`4-STANDARD CHARACTER MARK
`
`NO
`
`CURRENT OWNER INFORMATION
`
`20-OWNER AT PUBLICATION
`
`Glaxo Group Limited
`
`Glaxo Wellcome House, Berkeley Avenue
`Greenford, Middlesex,(cid:160)UB60NN
`
`
`
`ENTITY
`
`CITIZENSHIP
`
`INTERNATIONAL CLASS
`
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)DESCRIPTION TEXT
`
`INTERNATIONAL CLASS
`
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)DESCRIPTION TEXT
`
`03-CORPORATION
`
`GB2
`
`GOODS AND SERVICES
`
`016
`
`Printed materials, namely, pamphlets and brochures featuring the treatment and
`prevention of cardiovascular diseases and disorders
`
`042
`
`Medical and scientific research, namely, conducting clinical trials for pharmaceutical
`preparations for the treatment and prevention of cardiovascular diseases and
`disorders
`
`GOODS AND SERVICES CLASSIFICATION
`
`INTERNATIONAL
`CLASS
`
`016
`
`FIRST USE DATE
`
`NONE
`
`INTERNATIONAL
`CLASS
`
`042
`
`FIRST USE DATE
`
`NONE
`
`FIRST USE IN
`COMMERCE
`DATE
`
`FIRST USE IN
`COMMERCE
`DATE
`
`NONE
`
`CLASS STATUS
`
`6-ACTIVE
`
`NONE
`
`CLASS STATUS
`
`6-ACTIVE
`
`CHANGE IN REGISTRATION
`
`DISCLAIMER W/PREDETER TXT
`
`PSEUDO MARK
`
`MISCELLANEOUS INFORMATION/STATEMENTS
`
`NO
`
`"SELECTIVE TREATMENT OF ATHEROSCLEROSIS:DARAPLADIB INIHIBITS LP-
`PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS"
`
`STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB
`INIHIBITS LP-PLA TWO WITH ANTI-INFLAMMATORY AND PLAQUE
`STABILISING EFFECTS
`
`DATE
`
`08/02/2010
`
`08/02/2010
`
`05/12/2010
`
`05/03/2010
`
`PROSECUTION HISTORY
`
`ENT CD
`
`ENT TYPE
`
`DESCRIPTION
`
`MAB6
`
`ABN6
`
`TCCA
`
`TCCA
`
`EX2G
`
`O
`
`S
`
`I
`
`I
`
`S
`
`ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
`
`ABANDONMENT - NO USE STATEMENT FILED
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`EXTENSION 2 GRANTED
`
`ENT NUM
`
`037
`
`036
`
`035
`
`034
`
`033
`
`01/30/2010
`
`12/21/2009
`
`01/29/2010
`
`12/21/2009
`
`10/29/2009
`
`07/22/2009
`
`06/29/2009
`
`07/22/2009
`
`06/29/2009
`
`06/02/2009
`
`06/02/2009
`
`12/30/2008
`
`10/07/2008
`
`09/17/2008
`
`EXT2
`
`AITU
`
`EEXT
`
`TCCA
`
`EX1G
`
`EXT1
`
`AITU
`
`EEXT
`
`ARAA
`
`REAP
`
`NOAM
`
`PUBO
`
`NPUB
`
`S
`
`A
`
`I
`
`I
`
`S
`
`S
`
`A
`
`I
`
`I
`
`I
`
`O
`
`A
`
`O
`
`EXTENSION 2 FILED
`
`CASE ASSIGNED TO INTENT TO USE PARALEGAL
`
`TEAS EXTENSION RECEIVED
`
`TEAS CHANGE OF CORRESPONDENCE RECEIVED
`
`EXTENSION 1 GRANTED
`
`EXTENSION 1 FILED
`
`CASE ASSIGNED TO INTENT TO USE PARALEGAL
`
`TEAS EXTENSION RECEIVED
`
`ATTORNEY REVOKED AND/OR APPOINTED
`
`TEAS REVOKE/APPOINT ATTORNEY RECEIVED
`
`NOA MAILED - SOU REQUIRED FROM APPLICANT
`
`PUBLISHED FOR OPPOSITION
`
`NOTICE OF PUBLICATION
`
`032
`
`031
`
`030
`
`029
`
`028
`
`027
`
`026
`
`025
`
`024
`
`023
`
`022
`
`021
`
`020
`
`
`
`09/04/2008
`
`09/04/2008
`
`08/26/2008
`
`08/26/2008
`
`08/26/2008
`
`08/26/2008
`
`08/26/2008
`
`06/26/2008
`
`06/26/2008
`
`06/26/2008
`
`06/06/2008
`
`PREV
`
`ALIE
`
`CNSA
`
`XAEC
`
`GNEN
`
`GNEA
`
`CNEA
`
`GNFN
`
`GNFR
`
`CNFR
`
`TEME
`
`O
`
`A
`
`P
`
`I
`
`O
`
`O
`
`R
`
`O
`
`O
`
`R
`
`I
`
`LAW OFFICE PUBLICATION REVIEW COMPLETED
`
`ASSIGNED TO LIE
`
`APPROVED FOR PUB - PRINCIPAL REGISTER
`
`EXAMINER'S AMENDMENT ENTERED
`
`NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
`
`EXAMINERS AMENDMENT E-MAILED
`
`EXAMINERS AMENDMENT -WRITTEN
`
`NOTIFICATION OF FINAL REFUSAL EMAILED
`
`FINAL REFUSAL E-MAILED
`
`FINAL REFUSAL WRITTEN
`
`TEAS/EMAIL CORRESPONDENCE ENTERED
`
`CORRESPONDENCE RECEIVED IN LAW OFFICE
`
`019
`
`018
`
`017
`
`016
`
`015
`
`014
`
`013
`
`012
`
`011
`
`010
`
`009
`
`008
`
`06/06/2008
`
`06/06/2008
`
`12/07/2007
`
`12/07/2007
`
`12/07/2007
`
`12/03/2007
`
`10/26/2007
`
`10/25/2007
`
`ATTORNEY
`
`CORRESPONDENCE ADDRESS
`
`DOMESTIC REPRESENTATIVE
`
`PARTY TYPE
`
`NAME
`
`ADDRESS
`
`ENTITY
`
`CITIZENSHIP
`
`CRFA
`
`TROA
`
`GNRN
`
`GNRT
`
`CNRT
`
`DOCK
`
`MPMK
`
`NWAP
`
`I
`
`I
`
`O
`
`F
`
`R
`
`D
`
`O
`
`I
`
`TEAS RESPONSE TO OFFICE ACTION RECEIVED
`
`NOTIFICATION OF NON-FINAL ACTION E-MAILED
`
`NON-FINAL ACTION E-MAILED
`
`NON-FINAL ACTION WRITTEN
`
`ASSIGNED TO EXAMINER
`
`NOTICE OF PSEUDO MARK MAILED
`
`NEW APPLICATION ENTERED IN TRAM
`
`CURRENT CORRESPONDENCE INFORMATION
`
`007
`
`006
`
`005
`
`004
`
`003
`
`002
`
`001
`
`Christopher M. Hanes
`
`Christopher M. Hanes
`GlaxoSmithKline
`Five Moore Drive
`LGTM, C.3157.3D
`Research Triangle Park NC 27709
`
`Christopher M. Hanes
`
`PRIOR OWNER INFORMATION
`
`10-ORIGINAL APPLICANT
`
`Glaxo Group Limited
`
`Glaxo Wellcome House, Berkeley Avenue
`Greenford, Middlesex,(cid:160)UB60NN
`
`03-CORPORATION
`
`GB2
`
`
`
`STABILISE SELECTIVE
`
`TREATMENT OF
`
`ATHEROSCLEROSIS:
`
`DARAPLADIB INTPEITS
`
`LP-PLA2 WITH
`
`ANTI-INFLATVIMATORY AND
`PLAQUE STABTLISING EFFECTS
`
`